Varun Sardar, MD
Cardiovascular Disease · Jackson, MSNPI 1841642162
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (50.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Abbott at 56.6% of the total. Reporting peaked in 2022 at $16,962 and has fallen 82.3% since, to $3,009 in 2025. Among cardiovascular disease clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 300 payments — averaging $103.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$18K
- Abiomed$2K
- Penumbra, Inc.$2K
- Medtronic$2K
- Boehringer Ingelheim$1K
- AstraZeneca$995
- plus $5K from 36 others
What the payments were for
- Grants$15,75051%
- Travel & lodging$2,99610%
- Food & beverage$12,23439%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$1,797
- CARDIOMEMS$1,147
- TurboHawk$1,066
- Impella$905
- FLOWTRIEVER CATHETER, S$481
- CT THROMBECTOMY SYSTEM KIT$481
- FARXIGA$480
- JARDIANCE$424
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$278
- LifeSPARC$268
- BRILINTA$230
- CLOTTRIEVER BOLD CATHETER$169
- SYMPLICITY G3$150
- AVVIGO Guidance System$150
- EVOQUE$132
- CAMZYOS$125
- HawkOne$124
- (6575) Coronary Undivided$122
- Definity$120
- US Und$112
How this compares
$31,079 in reported general payments places this provider in the 90th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 64 | $51,129 |
| JardianceEmpagliflozin | 17 | $13,631 |
| FarxigaDapagliflozin Propanediol | 17 | $12,127 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 13 | $1,410 |
| ClopidogrelClopidogrel Bisulfate | 87 | $1,022 |
| Spironolactone | 66 | $668 |
| Metoprolol Succinate | 30 | $566 |
| Rosuvastatin Calcium | 40 | $483 |
| Hydralazine Hcl | 31 | $390 |
| Torsemide | 13 | $347 |
| Carvedilol | 49 | $334 |
| Atorvastatin Calcium | 30 | $297 |
| Losartan Potassium | 24 | $196 |
| Pantoprazole Sodium | 15 | $161 |
| Furosemide | 36 | $144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $113 | $51,12964 claims |
| Boehringer IngelheimJardiance | $1,204 | $13,63117 claims |
| AstraZenecaFarxiga | $995 | $12,12717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Jackson
- Donny StokesJackson$207K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Tahsin QarqishJackson$39K
- Christopher LatourJackson$33K
- Olurotimi BaderoJackson$20K
- Michael PaymentJackson$16K
- James HaysJackson$16K
- Douglas HarkinsJackson$14K
- Aditya SabharwalJackson$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.